Annual biomed conference is Israel’s ‘calling card’ for medical professionals interested in the latest in life science technology
Few people realize that more than one out of every four of the medicines, treatments, and technologies in use today have Israeli roots.
“Research in Israel is present in between 25% and 28% of the world’s successful biotech-based solutions,” according to Ruti Alon, a General Partner at Pitango Venture Capital and chairperson of the upcoming IATI-Biomed Conference, set to take place in Tel Aviv in May. “Many of the patents in pharmaceuticals that are now being used to treat cancer, heart problems, and much more were developed at Israeli institutions like Hebrew University or the Weizmann Institute,”
“All of the big pharma and health tech firms, from Merck to Pfizer to Sanofi, and many more, have R&D centers in Israel, and there are dozens, if not hundreds of start-ups that over the years have come up with unique solutions to some of the most pressing problems in biotech,” said Alon.
Some of those solutions and patents are part of the main treatments in some of the world’s most devastating diseases.
Exelon, for example, is a treatment for Alzheimer’s that helps patients cope with the disease and remain independent longer. Marketed by Novartis, the drug is based on research that was conducted at Hebrew University. Doxil, sold by Johnson and Johnson, effectively helps treat numerous cancers, and it, too, was developed at Hebrew U, along with researchers at Hadassah Medical Center. And, of course, there’s multiple sclerosis drug Copaxone, developed at the Weizmann Institute and marketed by Israel’s own Teva Pharmaceuticals.
Many of Israel’s biotech and life science solutions were first introduced to the world at the annual IATI-Biomed Conference, now in its 15th year.